Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Treace Medical Concepts (TMCI) EBIT (2020 - 2026)

Treace Medical Concepts filings provide 6 years of EBIT readings, the most recent being -$5.9 million for Q4 2025.

  • On a quarterly basis, EBIT fell 2802.94% to -$5.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$54.2 million, a 2.75% increase, with the full-year FY2025 number at -$54.2 million, up 2.75% from a year prior.
  • EBIT hit -$5.9 million in Q4 2025 for Treace Medical Concepts, up from -$15.7 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of -$204000.0 in Q4 2024 to a low of -$21.4 million in Q2 2024.
  • Median EBIT over the past 5 years was -$11.6 million (2022), compared with a mean of -$10.6 million.
  • Biggest five-year swings in EBIT: plummeted 8566.67% in 2021 and later soared 96.99% in 2024.
  • Treace Medical Concepts' EBIT stood at -$5.6 million in 2021, then soared by 37.52% to -$3.5 million in 2022, then tumbled by 93.94% to -$6.8 million in 2023, then soared by 96.99% to -$204000.0 in 2024, then tumbled by 2802.94% to -$5.9 million in 2025.
  • The last three reported values for EBIT were -$5.9 million (Q4 2025), -$15.7 million (Q3 2025), and -$17.0 million (Q2 2025) per Business Quant data.